<DOC>
	<DOC>NCT00179127</DOC>
	<brief_summary>The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children. The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.</brief_summary>
	<brief_title>Use of Insulin Glargine to Treat Diabetic Ketoacidosis</brief_title>
	<detailed_description />
	<mesh_term>Ketosis</mesh_term>
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Diabetic Ketoacidosis</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Ages 618 y.o. presenting to VCH E.R. with: Established history of insulin dependent diabetes AND: Chief c/o hyperglycemia or vomiting Venous pH &lt; 7.24 Serum Bicarbonate &lt; 18 Blood glucose &gt; 150 Urinary Ketones Age &lt; 6y.o. New onset diabetes Received IV insulin bolus prior to arrival to VCH E.R. Venous pH &gt; 7.24 Serum Bicarbonate &gt; 18 Pregnancy Received glargine within 12 hours prior to arrival to VCH E.R./PCCU</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Pediatrics</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Emergency Care</keyword>
	<keyword>Endocrinology</keyword>
	<keyword>Critical Care</keyword>
</DOC>